Evidence map›Paper›PMID 17898099›Full record

Trial reportThe New England journal of medicine2007

HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events.

Philip Barter, Antonio M Gotto, John C LaRosa, Jaman Maroni, Michael Szarek, Scott M Grundy, John J P Kastelein, Vera Bittner, Jean-Charles Fruchart, Treating to New Targets Investigators

2 registry-linked trialsAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in The New England journal of medicine, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT00327691. Cited by 535 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
535citing papers in PubMed, 9 pooled it
100.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00327691 phase4completed

The Effect Of LDL-Cholesterol, Lowering Beyond Currently Recommended Minimum Targets On Coronary Heart Disesse (CHD) Recurrence In Patients With Pre-Existing CHD

Ran1998Enrolled8,600Registered outcomes13Posted comparisons0ConditionsCardiovascular Disease, Cerebrovascular Accident, Coronary Heart DiseaseArmsAtorvastatin
PMID 17084252other papers from this trial
Open the trial in the graph
NCT02593487 phase4unknown statusstarted 2015, after this paper: background citation

Effect of Rosuvastatin Therapy on HDL2 Level and Antiatherosclerotic Reverse Cholesterol Transport Process in Chinses CAD Patients With Hyperlipidemia

Ran2015Enrolled300Registered outcomes1Posted comparisons0ConditionsCoronary Heart Disease, HyperlipemiaArmsRosuvastatin 10mg/d group, Rosuvastatin 20mg/d group
PMID 24595147PMID 23428644PMID 24739590PMID 22584085PMID 18955731PMID 24465490PMID 24528685other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

535 citing papers in PubMed, 9 syntheses or guidelines pooled it, 1,611 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Guideline
  9. Pooled it
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. The HDL lipidome is widely remodeled by fast food versus Mediterranean diet in 4 days.Metabolomics : Official journal of the Metabolomic Society · 2019
    Trial

475 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 8 institutions in 4 countries.

Philip BarterHeart Research Institute, Sydney, Australia. barterp@hri.org.au
Antonio M Gotto
John C LaRosa
Jaman Maroni
Michael Szarek
Scott M Grundy
John J P Kastelein
Vera Bittner
Jean-Charles Fruchart
Treating to New Targets Investigators
Pfizer (United States) · USCornell University · USInstitut Pasteur de Lille · FRSUNY Downstate Health Sciences University · USThe Heart Research Institute · AUThe University of Texas Southwestern Medical Center · USUniversity of Alabama at Birmingham · USUniversity of Amsterdam · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHigh-density lipoprotein (HDL) cholesterol levels are a strong inverse predictor of cardiovascular events. However, it is not clear whether this association is maintained at very low levels of low-density lipoprotein (LDL) cholesterol.

methodsA post hoc analysis of the recently completed Treating to New Targets (TNT) study assessed the predictive value of HDL cholesterol levels in 9770 patients. The primary outcome measure was the time to a first major cardiovascular event, defined as death from coronary heart disease, nonfatal non-procedure-related myocardial infarction, resuscitation after cardiac arrest, or fatal or nonfatal stroke. The predictive relationship between HDL cholesterol levels at the third month of treatment with statins and the time to the first major cardiovascular event was assessed in univariate and multivariate analyses and was also assessed for specific LDL cholesterol strata, including subjects with LDL cholesterol levels below 70 mg per deciliter (1.8 mmol per liter).

resultsThe HDL cholesterol level in patients receiving statins was predictive of major cardiovascular events across the TNT study cohort, both when HDL cholesterol was considered as a continuous variable and when subjects were stratified according to quintiles of HDL cholesterol level. When the analysis was stratified according to LDL cholesterol level in patients receiving statins, the relationship between HDL cholesterol level and major cardiovascular events was of borderline significance (P=0.05). Even among study subjects with LDL cholesterol levels below 70 mg per deciliter, those in the highest quintile of HDL cholesterol level were at less risk for major cardiovascular events than those in the lowest quintile (P=0.03).

conclusionsIn this post hoc analysis, HDL cholesterol levels were predictive of major cardiovascular events in patients treated with statins. This relationship was also observed among patients with LDL cholesterol levels below 70 mg per deciliter. (ClinicalTrials.gov number, NCT00327691 [ClinicalTrials.gov].).

Indexed as

AdultAgedAnticholesteremic AgentsApolipoproteinsAtorvastatinCardiovascular DiseasesCholesterol, HDLCholesterol, LDLCoronary DiseaseDouble-Blind MethodFemaleHeptanoic AcidsHumansHydroxymethylglutaryl-CoA Reductase InhibitorsHypercholesterolemiaMaleAnticholesteremic AgentsApolipoproteinsAtorvastatinCholesterol, HDLCholesterol, LDLHeptanoic AcidsHydroxymethylglutaryl-CoA Reductase InhibitorsPyrroles

Identifiers

PMID17898099
OpenAlexW2158057499

What OpenQuestion holds

Texttitle and abstract
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.